Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03011658
Other study ID # PMVIDS&RC/IEC/OMR/DN/0004-15
Secondary ID
Status Completed
Phase N/A
First received January 4, 2017
Last updated December 18, 2017
Start date January 2016
Est. completion date December 2017

Study information

Verified date December 2017
Source Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oral lichen planus (OLP) is a T-cell mediated chronic immunological disease directed to a still unknown antigen. It is a mucocutaneous and a psychosomatic disorder, with unknown prevalence rate; however studies suggest an incidence of 0.02 to 0.22% among the Indian population. 75% of patients with cutaneous lichen planus also experience oral lesions and may be precipitated or exacerbated by psychosocial stressors.

In conditions like pain, anxiety and stress, many metabolic and endocrine changes occur in the body, the most common effect of which is increased cortisol level in blood. This hormone is a 21-carbon corticosteroid secreted by adrenal cortex and regulates the metabolism of carbohydrates, fats, proteins and water. Also known as stress hormone, cortisol is a decisive index in stressful situations.

This study is intended to correlate the serum cortisol levels with anxiety and depression in patients with symptomatic oral lichen planus. This study attempts to evaluate psychological anxiety and depression in oral lichen planus subjects using Hospital Anxiety and Depression Scale ( HADS) and correlating with their serum cortisol levels.

To understand and explore the etiopathogenesis for better management of oral lichen planus.


Description:

Oral lichen planus (OLP) is a T-cell mediated chronic immunological disease directed to a still unknown antigen. It is a mucocutaneous and a psychosomatic disorder, with unknown prevalence rate; however studies suggest an incidence of 0.02 to 0.22% among the Indian population. 75% of patients with cutaneous lichen planus also experience oral lesions and may be precipitated or exacerbated by psychosocial stressors.

In conditions like pain, anxiety and stress, many metabolic and endocrine changes occur in the body, the most common effect of which is increased cortisol level in blood. This hormone is a 21-carbon corticosteroid secreted by adrenal cortex and regulates the metabolism of carbohydrates, fats, proteins and water. Also known as stress hormone, cortisol is a decisive index in stressful situations.

This study is intended to correlate the serum cortisol levels with anxiety and depression in patients with symptomatic oral lichen planus.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion criteria

- Clinical features with burning sensation on eating spicy food.

- Patients with symptomatic Oral lichen planus evaluated clinically and histologically.

Exclusion criteria:

- Patients not willing to be part of the study.

- Patients who are on corticosteroid therapy.

- Patients with endocrinal disorders which can alter adrenal gland function.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
venepuncture
for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus

Locations

Country Name City State
India Panineeya Institute of Dental Sciences Hyderabad Telangana

Sponsors (1)

Lead Sponsor Collaborator
Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum- cortisol levels from venous blood. 1 year
Secondary Hospital Anxiety and Depression scale 1 year
See also
  Status Clinical Trial Phase
Completed NCT06332365 - Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers N/A